Skip to main content
Log in

Clinical course of patients with chronic hepatitis B with viral breakthrough during long-term lamivudine treatment

  • Published:
Journal of Gastroenterology Aims and scope Submit manuscript

Abstract

Background

We evaluated the clinical course of patients with chronic hepatitis B who showed viral breakthrough during long-term lamivudine therapy.

Methods

We initially studied 141 patients treated with lamivudine for 1 year or more, and 49 patients who showed viral breakthrough were the subjects of this study. Their mean lamivudine administration period was 2.3 ± 0.9 years.

Results

After viral breakthrough, breakthrough hepatitis occurred in 47 patients (95.9%), but did not occur in the other 2 (4.1%). Four of the 47 patients with breakthrough hepatitis were observed without further treatment, and the alanine transferase (ALT) level was normalized in 2 of them but fluctuated in the other 2. Breakthrough hepatitis was treated by injection of glycyrrhizin or ursodeoxycholic acid administration in 36 of the remaining 43 patients, and by antiviral drug administration in the other 7 (entecavir in 2 patients, adefovir in 2, and interferon in 3). The ALT level was normalized in 5 of the 36 patients treated with glycyrrhizin or ursodeoxycholic acid, but persistently fluctuated in the other 31. In those with normalized ALT after the occurrence of breakthrough hepatitis, the peak ALT level at that point was significantly lower (86 ± 47 IU/l) than that in the patients without normalization (206 ± 167 IU/l).

Conclusions

These results showed that there were a few patients who did not develop breakthrough hepatitis after showing viral breakthrough, and some who showed normalization of the ALT level after the occurrence of breakthrough hepatitis, but in many patients, ALT continuously fluctuated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. CL Lai RN Chien NWY Leung TT Chang R Guan DI Tai et al. (1998) ArticleTitleA 1-year trial of lamivudine for chronic hepatitis B N Engl J Med 339 61–8 Occurrence Handle9654535

    PubMed  Google Scholar 

  2. JL Dienstag ER Schiff TL Wright RP Perrillo HW Hann Z Goodman et al. (1999) ArticleTitleLamivudine as initial treatment for chronic hepatitis B in the United States N Engl J Med 341 1256–63 Occurrence Handle10528035

    PubMed  Google Scholar 

  3. YO Kweon ZD Goodman JL Dienstag ER Schiff NA Brown E Burchardt et al. (2001) ArticleTitleDecreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B J Hepatol 35 749–55 Occurrence Handle11738102

    PubMed  Google Scholar 

  4. GC Farrell (2000) ArticleTitleClinical potential of emerging new agents in hepatitis B Drugs 60 701–10 Occurrence Handle11085196

    PubMed  Google Scholar 

  5. YF Liaw RN Chien CT Yeh SL Tsai CM Chu (1999) ArticleTitleAcute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy Hepatology 30 567–72 Occurrence Handle10421670

    PubMed  Google Scholar 

  6. S Nafa S Ahmed D Tavan C Pichoud F Berby L Studyver et al. (2000) ArticleTitleEarly detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B Hepatology 32 1078–88 Occurrence Handle11050059

    PubMed  Google Scholar 

  7. MF Yuen T Kato M Mizokami AO Chan JC Yuen HJ Yuan et al. (2003) ArticleTitleClinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations J Hepatol 39 850–5 Occurrence Handle14568270

    PubMed  Google Scholar 

  8. R Kumashiro R Kuwahara T Ide Y Koga T Arinaga A Hisamochi et al. (2003) ArticleTitleSubclones of drug-resistant hepatitis B virus mutants and the outcome of breakthrough hepatitis in patients treated with lamivudine Intervirology 46 350–4 Occurrence Handle14688451

    PubMed  Google Scholar 

  9. C Mayerat A Mantegani PC Frei (1999) ArticleTitleDoes hepatitis B virus (HBV) genotype influence the clinical outcome of HBV infection? J Viral Hepat 6 299–304 Occurrence Handle10607244

    PubMed  Google Scholar 

  10. E Orito M Mizokami H Sakugawa K Michitaka K Ishikawa T Ichida et al. (2001) ArticleTitleA case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group Hepatology 33 218–23 Occurrence Handle11124839

    PubMed  Google Scholar 

  11. F Suzuki A Tsubota N Akuta T Someya M Kobayashi Y Suzuki et al. (2002) ArticleTitleInterferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy J Gastroenterol 37 922–7 Occurrence Handle12483247

    PubMed  Google Scholar 

  12. S Kobayashi K Shimada H Suzuki K Tanikawa M Sata (2000) ArticleTitleDevelopment of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD motif Hepatol Res 17 31–42

    Google Scholar 

  13. MF Yuen E Sablon CK Hui HJ Yuan H Decraemer CL Lai (2001) ArticleTitleFactors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy Hepatology 34 785–91 Occurrence Handle11584376

    PubMed  Google Scholar 

  14. T Ide R Kumashiro T Hino S Murashima K Ogata Y Koga et al. (2001) ArticleTitleTranscription-mediated amplification is more useful in the follow-up of patients with chronic hepatitis B treated with lamivudine Hepatol Res 21 76–84 Occurrence Handle11470630

    PubMed  Google Scholar 

  15. N Akuta F Suzuki M Kobayashi M Matsuda J Sato K Takagi et al. (2003) ArticleTitleVirological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy J Med Virol 71 504–10 Occurrence Handle14556262

    PubMed  Google Scholar 

  16. NW Leung CL Lai TT Chang R Guan CM Lee KY Ng et al. (2001) ArticleTitleExtended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy Hepatology 33 1527–32 Occurrence Handle11391543

    PubMed  Google Scholar 

  17. YF Liaw NW Leung TT Chang R Guan DI Tai KY Nq et al. (2000) ArticleTitleEffects of extended lamivudine therapy in Asian patients with chronic hepatitis B Gastroenterology 119 172–80 Occurrence Handle10889166

    PubMed  Google Scholar 

  18. JL Dienstag RD Goldin EJ Heathcote HW Hann M Woessner SL Stephenson et al. (2003) ArticleTitleHistological outcome during long-term lamivudine therapy Gastroenterology 124 105–17 Occurrence Handle12512035

    PubMed  Google Scholar 

  19. SF Lok CL Lai N Leung GB Yao ZY Cui ER Schiff et al. (2003) ArticleTitleLong-term safety of lamivudine treatment in patients with chronic hepatitis B Gastroenterology 125 1714–22 Occurrence Handle14724824

    PubMed  Google Scholar 

  20. VJ Desmet M Gerber JH Hoofnagle M Manns PJ Scheuer (1994) ArticleTitleClassification of chronic hepatitis: diagnosis, grading and staging Hepatology 19 1513–20

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ide, T., Kumashiro, R., Kuwahara, R. et al. Clinical course of patients with chronic hepatitis B with viral breakthrough during long-term lamivudine treatment. J Gastroenterol 40, 625–630 (2005). https://doi.org/10.1007/s00535-005-1597-9

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00535-005-1597-9

Key words

Navigation